• Explore /
  • Poster
  • / The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.

The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.

Abstract Poster

Authors

null

Danilo Giffoni M. M. Mata

Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Danilo Giffoni M. M. Mata , Kelvin K. Chan , Andrea Eisen , Rossanna C. Pezo , Ines B. Menjak , Maureen E. Trudeau

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 538)

DOI

10.1200/JCO.2022.40.16_suppl.538

Abstract #

538

Poster Bd #

310

Abstract Disclosures

Similar Posters

First Author: Katherine Lovat

First Author: Rosana Gnanajothy

Poster

2015 ASCO Annual Meeting

Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.

Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.

First Author: Sarah Schellhorn Mougalian

First Author: Sofia Torres